Objective
The main goal of the TRINITY project is to show that existing immune-modulating drugs can be reused in a more targeted way to treat autoimmune diseases. TRINITY focuses on five already-approved medications known as JAK inhibitors and aims to identify which of them are most likely to be effective across type 1 diabetes (T1D), lupus (SLE), and multiple sclerosis (MS).
To achieve this, TRINITY builds on extensive findings from an earlier research effort called COMET (Common Mechanisms in Autoimmune Disease), which was supported by international diabetes, lupus, and MS research organizations. That project mapped shared immune pathways across autoimmune diseases and revealed important similarities and differences in how immune cells become activated. TRINITY uses this foundation to apply a data-driven strategy, allowing researchers to prioritize drug candidates based on biological mechanisms rather than trial-and-error testing.
TRINITY will directly examine how blocking JAK signaling affects immune cell behavior in T1D, SLE, and MS. Researchers will study immune cells taken from people with these diseases and test how different JAK inhibitors influence immune activation, inflammatory signaling, and the ability of cells to withstand stress. By using the same standardized laboratory methods across all diseases, TRINITY will enable direct comparisons of drug effects and reveal which inhibitors most effectively calm harmful immune responses.
This cross-disease approach is especially important for identifying treatments with the greatest potential to translate to T1D, where current immune therapies have had limited success. By comparing responses side by side, TRINITY aims to pinpoint the Janus kinase (JAK) inhibitors that best target disease-relevant immune pathways while minimizing unnecessary immune suppression.
Overall, the TRINITY project seeks to create a clear, evidence-based framework for selecting the most promising JAK inhibitors for future development. Because the drugs studied are already approved for other conditions, the project has the potential to significantly speed up their repurposing and support the development of safer, more precise, and more effective treatments for people living with autoimmune diseases.
Background Rationale
Autoimmune diseases such as type 1 diabetes (T1D), lupus (SLE), and multiple sclerosis (MS) occur when the immune system becomes overactive and mistakenly attacks the body’s own tissues. Although these diseases affect different organs, they are driven by related immune processes. At the same time, people with the same disease can experience very different symptoms and respond differently to treatment. This makes it difficult to develop therapies that work well for most patients and to design clinical trials that clearly show who will benefit.
To better understand these differences, a previous large research effort called the COMET project studied immune cells from people with several autoimmune diseases in great detail. Using advanced methods to measure immune cell types, metabolism, and gene activity, COMET uncovered an important difference between diseases. In SLE and MS, immune cells were highly active and used large amounts of energy to drive inflammation. In contrast, immune cells from people with T1D looked much more similar to those from healthy individuals in terms of energy use, but showed specific changes in how they responded to immune signals.
One of the key signaling changes identified in type 1 diabetes involved interleukin-7 (IL-7), a molecule that helps control immune cell survival and activation. Increased IL-7 signaling has been linked to the persistence of harmful immune cells in T1D. IL-7 sends its signals through a communication system inside immune cells known as the Janus kinase (JAK)/STAT pathway. Changes in this pathway have also been linked to lupus and multiple sclerosis, although the way immune cells are activated differs between these diseases.
Because of its central role in immune signaling, the JAK/STAT pathway has become an important target for treatment. Drugs called JAK inhibitors block parts of this pathway and can reduce multiple inflammatory signals at once. Many JAK inhibitors are already approved for clinical use and have been shown to be effective in diseases such as rheumatoid arthritis and SLE and more recently in T1D. However, different JAK inhibitors act on different parts of the pathway, which means they can have different effects and side effects.
So far, most studies of JAK inhibitors have focused on individual diseases and have tested drugs one at a time. This approach has created a fragmented picture only and has limited the identification of the most promising JAK inhibitors, especially for T1D.
The TRINITY project was designed to overcome these limitations by directly comparing how immune signaling works across T1D, SLE and MS. By focusing on shared and disease-specific immune signals rather than broad immune activation alone, TRINITY aims to provide a clearer scientific basis for selecting and repurposing JAK inhibitors as more targeted and effective treatments for autoimmune diseases.
Description of Project
TRINITY investigates how the immune systems of people with type 1 diabetes (T1D), lupus (SLE), and multiple sclerosis (MS) respond to inflammatory signals that cause the body to attack itself. Although these diseases affect different organs, they share common immune pathways, and people with the same disease often respond very differently to treatment. This makes it challenging to identify therapies that are both effective and safe.
Rather than focusing on broad immune overactivation, TRINITY concentrates on specific immune signaling pathways that may be driving disease in different ways. The project builds on earlier research showing that immune cells from people with SLE and MS are highly metabolically active, while immune cells from people with T1D look much more like those of healthy individuals. In T1D, however, immune cells show subtle but important changes in how they respond to inflammatory signals, particularly those involving the immune messenger interleukin-7 (IL-7).
IL-7 sends signals through a communication system inside immune cells known as the Janus kinase (JAK)/STAT pathway. This pathway helps control immune cell survival, activation, and function and plays an important role in autoimmune disease. TRINITY tests five already-approved JAK inhibitor medications which block different parts of this pathway, to determine how effectively they can calm harmful immune responses across T1D, SLE, and MS.
By studying immune cells from people with all three autoimmune diseases side by side, TRINITY aims to identify which immune signals are shared and which are disease-specific. Using the same laboratory methods across all groups allows researchers to directly compare how different JAK inhibitors affect immune cell activation, inflammation, and survival under controlled conditions. This approach helps reveal why certain drugs may work better in one disease than another.
Because these JAK inhibitor medications are already approved for use in humans, TRINITY’s findings could quickly support their repurposing for autoimmune diseases where treatment options remain limited. In particular, the project seeks to identify drugs that may help protect insulin-producing cells in T1D while also reducing damaging immune activity in lupus and MS.
Overall, TRINITY aims to provide a clearer understanding of how immune signaling drives autoimmune disease and to use this knowledge to guide more targeted and personalized treatments. By focusing on shared immune mechanisms rather than disease labels alone, the project has the potential to accelerate the development of safer and more effective therapies for people living with autoimmune conditions.
Anticipated Outcome
TRINITY is designed to quickly identify which existing JAK inhibitor medications can safely and effectively calm the immune system in people with type 1 diabetes (T1D), lupus (SLE), and multiple sclerosis (MS), helping move the best options into clinical trials faster. The team of TRINITY will test five approved JAK inhibitors, namely baricitinib, deucravacitinib, ritlecitinib, and two others, directly on immune cells from patients to see which mediciations most reliably reduce harmful immune signals.
What patients can expect: TRINITY aims to deliver clear evidence showing which JAK inhibitors work best and why, supporting smarter, safer repurposing for T1D, SLE, and MS. By measuring detailed cell changes and signaling patterns, TRINITY will develop actionable biomarkers tools that help match the right medication to the right patient at the right time. It will also create a standardized testing platform so results can be compared across clinics and diseases, speeding multi site validation and future trials.
Ultimately, the goal is to protect insulin producing cells in T1D and reduce damaging immune activity in SLE and MS, thus bringing targeted, more personalized treatments closer to patients sooner.
Relevance to T1D
Janus kinase (JAK) inhibitors represent a promising new treatment for type 1 diabetes because they act through two coordinated mechanisms at the same time: They calm the overactive immune system while directly protecting the insulin producing beta cells in the pancreas.
On the immune side, JAK inhibitors dampen cytokine signaling that drives T cell activity, including pathways leading to Th17 differentiation, and they lower the expression of HLA class I and class II molecules on professional antigen presenting cells. This makes it harder for immune cells to recognize and attack beta cells, reduces chemokine production that would otherwise attract more immune cells, and ultimately lessens insulitis and immune infiltration into the pancreatic islets.
On the beta cell side, JAK inhibitors decrease the aberrant HLA class I display that makes beta cells targets for cytotoxic immune cells, relieve endoplasmic reticulum (ER) stress to support normal cellular function, block interferon induced apoptosis to prevent inflammatory cell death, and curb pro inflammatory chemokine secretion that fuels local inflammation.
This dual action sets JAK inhibitors apart from earlier immunosuppressive approaches, which typically targeted either the immune system or beta cell stress, but not both. The TRINITY project now offers a timely opportunity to advance this dual mechanism strategy to accelerate the path to curing type 1 diabetes.